Quality of Life Implications of Bisphosphonate-Associated Osteonecrosis of the Jaw
Open Access
- 1 January 2011
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 16 (1), 121-132
- https://doi.org/10.1634/theoncologist.2010-0183
Abstract
Purpose.: Potentially debilitating, osteonecrosis of the jaw (ONJ) is an emerging complication of bisphosphonates. However, its effect on quality of life (QoL) is unknown. We determined the ONJ-related QoL decline in a cancer patient cohort. Patients and Methods.: Thirty-four cancer patients with bisphosphonate-associated ONJ completed a telephone survey (October 2007 through May 2008). The Oral Health Impact Profile 14 (OHIP) retrospectively assessed participant oral health–related QoL before and after ONJ. Standardized ONJ descriptions were developed in a multidisciplinary, iterative process and were evaluated with three frequently used preference-based QoL measurement methods on a 0 (death) to 1 (perfect health) scale: Visual Analogue Scale (VAS), Time Trade-Off (TTO), and EQ-5D. Results.: ONJ significantly (p < .001) increased OHIP scores (worse QoL) for additive (3.56–16.53) and weighted (7.0–17.5) methods. Seven individual OHIP items significantly increased (Bonferroni correction p < .0035): pain, eating discomfort, self-consciousness, unsatisfactory diet, interrupted meals, irritability, and decreased life satisfaction. Mean preference-based QoL values significantly decreased (p < .001) with worsening ONJ stage (VAS, TTO, and EQ-5D): no ONJ (0.76, 0.86, 0.82), ONJ stage 1 (0.69, 0.82, 0.78), ONJ stage 2 (0.51, 0.67, 0.55), and ONJ stage 3 (0.37, 0.61, 0.32). As ONJ worsened, EQ-5D domain scores significantly increased (p < .001). Pain/discomfort and anxiety/depression contributed most to declining QoL. Conclusions.: ONJ significantly affects QoL, a detriment that increases with worsening ONJ. QoL impairments for ONJ stages 2 and 3 are similar to other treatment side effects that influence decision-making. Bisphosphonate-associated ONJ QoL is an important consideration for patients, clinicians, and policy makers.Keywords
Funding Information
- American Society of Clinical Oncology Young Investigator Award
- Dana-Farber Harvard Cancer Center Timely Opportunity Award
- Program in Cancer Outcomes Research Training (5R25CA 092203-04)
- Department of Medicine
- Beth Israel Deaconess Medical Center
- Clinical Investigator Training Program: Beth Israel Deaconess Medical Center–Harvard/MIT Health Sciences and Technology
- Pfizer Inc.
- Merck & Co.
This publication has 95 references indexed in Scilit:
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatmentGynecologic Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast CancerJournal of Clinical Oncology, 2008
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control StudyJournal of Oral and Maxillofacial Surgery, 2008
- Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective StudyThe Oncologist, 2008
- Baseline Characteristics and Treatment Preferences of Oral Surgery PatientsJournal of Oral and Maxillofacial Surgery, 2007
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- What Value Health?Applied Health Economics and Health Policy, 2005